Key Takeaways
- AbbVie entered the large and competitive obesity market by licensing Gubra’s Phase I amylin analog GUBamy (GUB014295) for $350m up front and up to $1.875bn in fees plus royalties.
- Established obesity player Novo also announced a collaboration, paying up to $354m in upfront and milestone fees per target under a cardiometabolic disease discovery alliance with Gensaic.
- AbbVie is behind in the amylin field where experienced players – including Novo – are ahead, but it is among other big pharma companies and start-ups just establishing a foothold in obesity.
Big pharma’s appetite for the next big play in the mega-blockbuster obesity market seems insatiable, but two companies aim to feed their pipelines with sizeable collaborations announced on 3 March
The Gubra deal marks AbbVie’s first foray into the obesity space, while Novo’s alliance with Gensaic continues the Danish pharma’s buildout of a broad research and development pipeline in obesity and related indications
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
